{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Comparison between arms at Day 28 of treatment","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.289","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Comparison between Day 1 and Day 28","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Comparison between Day 1 and day 28","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.002","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Comparison between Day 28 and Day 56 of treatment for the armodafinil arm","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.449","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.2","value":"65.0"},{"groupId":"OG001","spread":"14.3","value":"57.2"}]}],"title":"Day 1(n=18, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.4","value":"48.8"},{"groupId":"OG001","spread":"18.4","value":"41.5"}]}],"title":"Day 28 (n=19, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.9","value":"43.2"},{"comment":"Day 56 data was only evaluated for the Armodafinil arm","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"Day 56 (n=15)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Survey measuring fatigue. The scale contains 9 items; range=0-90 (0-10 per item). Mild = 1-3 Moderate = 4-7 Severe = 8-10","dispersionType":"Standard Deviation","groups":[{"description":"The patients receive armodafinil for all 56 days of the study.\n\nArmodafinil taken orally at 150 mg daily.","id":"OG000","title":"Armodafinil"},{"description":"These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).\n\nPlacebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.","id":"OG001","title":"Placebo-First"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Day 1, Day 28 and Day 56","title":"BFI Score","type":"PRIMARY","unitOfMeasure":"units on a scale"}